A multicenter prospective trial estimating the persistence of remission after stopping BCMA-CD3 bispecific antibody in multiple myeloma patients with major M-spike response by use MaldiTOF-based high sensitivity monitoring - SWE-DISCO-MM1
Latest Information Update: 16 Mar 2026
At a glance
- Drugs Elranatamab (Primary) ; Teclistamab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms SWE-DISCO-MM1
Most Recent Events
- 16 Mar 2026 New trial record